Effects of long-term administration of octreotide in portal vein-stenosed rats

Hepatology

Volumn 23, Issue 3, 1996, Pages 537-543

  Lin, Han Chieh ^a,b   Yang, May C M ^b   Hou, Ming Chih ^a   Shu Min, L I ^a   Huang, Y I Tsau ^a   Yu, P I Chin ^b   Tsai, Yang T E ^a   Lee, Shou Dong ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; GLUCAGON BLOOD LEVEL; MALE; MESENTERIC ARTERY OCCLUSION; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PORTAL VEIN OBSTRUCTION; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; VASCULAR RESISTANCE;

EID: 0029967589     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510230319     Document Type: Article

References (10)

1. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marback P, Petcher TJ, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982;31:1133-1140.
2. Hwang SJ, Lin HC, Chang CF, Lee FY, Lu CW, Hsia HC, Wang SS, et al. A randomized controlled trial comparing octreotide and vasopressin in the control of acute esophageal variceal bleeding. J Hepatol 1992;16:320-325.
3. Sung JJY, Chung SCS, Lai CW, Chan FKL, Leung JWC, Yung MY, Kassianides C, et al. Octreotide infusion or emergency sclerotherapy for variceal haemorrhage. Lancet 1993;342:637-641.
4. Silvain C, Carpentier S, Sautereau D, Czernichow B, Métreau JM, Fort E, Ingrand P, et al. Terlipressin plus transdermal nitroglycerin vs. octreotide in the control of acute bleeding from esophageal varices: a multicenter randomized trial. HEPATOLOGY 1994;18:61-65.
5. Cerini R, Lee SS, Hadengue A, Koshy A, Girod C, Lebrec D. Circulatory effects of somatostatin analogue in two conscious rat models of portal hypertension. Gastroenterology 1988;94:703-708.
6. + retention in portal hypertensive rats. Gastroenterology 1993;104:575-579.
7. Eriksson LS, Brundin T, Söderlund C, Wahren J. Haemodynamic effects of a long-acting somatostatin analogue in patients with liver cirrhosis. Scand J Gastroenterol 1987;22:919-925.
8. Pringle SD, McKee RF, Garden OJ, Lorimer AR, Carter DC. The effect of a long-acting somatostatin analogue on portal and systemic haemodynamics in cirrhosis. Aliment Pharmacol Ther 1988;2:451-459.
9. McCormick PA, Dick R, Siringo S, Wagstaff D, Chesta J, McIntyre N, Burroughs AK. Octreotide reduces azygos blood flow in cirrhotic patients with portal hypertension. Eur J Gastroenterol Hepatol 1990;2:489-492.
10. Lin HC, Tsai YT, Lee FY, Lee SD, Hsia HC, Lin WJ, Lo KJ. Hemodynamic evaluation of octreotide in patients with hepatitis B-related cirrhosis. Gastroenterology 1992;103:229-234.